| Literature DB >> 35780012 |
Ana Lisa Valenciano1, Maria G Gomez-Lorenzo2, Joel Vega-Rodríguez3, John H Adams4, Alison Roth5.
Abstract
The Plasmodium liver stage represents a vulnerable therapeutic target to prevent disease progression as the parasite resides in the liver before clinical representation caused by intraerythrocytic development. However, most antimalarial drugs target the blood stage of the parasite's life cycle, and the few drugs that target the liver stage are lethal to patients with a glucose-6-phosphate dehydrogenase deficiency. Furthermore, implementation of in vitro liver models to study and develop novel therapeutics against the liver stage of human Plasmodium species remains challenging. In this review, we focus on the progression of in vitro liver models developed for human Plasmodium spp. parasites, provide a brief review on important assay requirements, and lastly present recommendations to improve models to enhance the discovery process of novel preclinical therapeutics. Published by Elsevier Ltd.Entities:
Keywords: Plasmodium falciparum; Plasmodium vivax; exoerythrocytic; hepatocyte; liver stage; malaria
Mesh:
Substances:
Year: 2022 PMID: 35780012 PMCID: PMC9378454 DOI: 10.1016/j.pt.2022.05.014
Source DB: PubMed Journal: Trends Parasitol ISSN: 1471-4922